Showing results (51-60 of 56) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.Pharmacogenetics and Genomics|June 12, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosisNana Agyemang, Kimberly K Scarsi, Paxton Baker, et al.Nature Communications|June 10, 2022
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulationSuyash Deodhar, Brady Sillman, Aditya N Bade, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.Pageof 6